Скачать с ютуб THT 2025: The FASTR Trial в хорошем качестве

THT 2025: The FASTR Trial

THT Conference 2025 - Positive safety and efficacy outcomes were found of the reprieve decongestion management system (DMS; Reprieve Cardiovascular, Inc) for the treatment of acute decompensated heart failure (ADHF). Urinary sodium excretion was seen to be significantly higher in the reprieve DMS arm than in the control arm, and there were fewer UTI infections in ADHF patients receiving the reprieve DMS. Dr James Udelson (Tufts Medical Center, Boston, MA, US) joins us to discuss the findings from FASTR (NCT05174312), a prospective, randomized, phase-two pilot trial investigating the reprieve DMS in comparison to optimal diuretic therapy for ADHF patients. The primary efficacy endpoint was the total urine sodium output, and the primary safety endpoint includes clinically significant acute kidney injury, severe electrolyte abnormality, symptomatic hypotension or hypertensive emergency. Interview Questions: 1. What is the importance behind the FASTR trial? 2. What was the study design and patient population? 3. What were the key findings? 4. How should these findings impact clinical practice? 5. What further research is needed? Recorded remotely from Boston, 2025 Editors: Yazmin Sadik, Jordan Rance Videographers: David Ben-Harosh, Oliver Miles Support: This is an independent interview produced by Radcliffe Cardiology. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook:   / radcliffecardiology   Follow us on X: https://x.com/radcliffeCARDIO